免疫治疗中的[18F]FDG PET:证据、影像指南与肿瘤实践之间的差距
本文针对免疫治疗中[18F]FDG PET的应用,指出国际肿瘤指南对黑色素瘤和非小细胞肺癌(NSCLC)未作具体推荐,而核医学学会联合指南推荐在免疫治疗前、早期疗效评估及考虑停药时联合使用PET与CT。作者批判性综述比较PET与CT疗效评估的文献,认为PET在鉴别假性进展与真进展方面价值有限,但在新辅助免疫治疗疗效评估和停药前评估两个场景可能优于CT,并强调临床实施前需生成稳健证据。
要点
- 国际肿瘤指南对黑色素瘤和NSCLC免疫治疗中[18F]FDG PET无具体推荐。
- 核医学学会联合指南推荐免疫治疗前、早期疗效评估及考虑停药时使用PET联合CT。
- PET在早期疗效评估中鉴别假性进展与真进展价值有限。
核心结论
- 当前国际肿瘤指南未对黑色素瘤和NSCLC免疫治疗中[18F]FDG PET作出具体声明。
- 核医学学会联合指南推荐在免疫治疗前、早期疗效评估及考虑停药时使用[18F]FDG PET联合CT。
- [18F]FDG PET在早期疗效评估中鉴别假性进展与真进展价值有限。
- [18F]FDG PET在新辅助免疫治疗疗效评估和停药前评估两个场景可能优于CT。
- 临床实施前需生成稳健证据以确保资源优化分配和更好患者照护。
研究设计与样本
- 本文为批判性文献综述,比较[18F]FDG PET与CT在免疫治疗患者疗效评估中的证据。
主要发现
- 在需要准确鉴别假性进展与真进展的早期疗效评估中,[18F]FDG PET价值有限。
- 在新辅助免疫治疗疗效评估或停药前评估中,[18F]FDG PET因高阴性预测值可能优于CT。
关键数值与推荐
- 核医学学会联合指南推荐在免疫治疗开始前、早期疗效评估及考虑停药时使用[18F]FDG PET联合CT。
临床怎么用
- 临床可依据核医学学会联合指南,在免疫治疗前、早期疗效评估及考虑停药时联合使用[18F]FDG PET与CT。
- 早期疗效评估中不应依赖[18F]FDG PET鉴别假性进展与真进展。
- 在新辅助免疫治疗疗效评估和停药前评估中可考虑[18F]FDG PET以利用其高阴性预测值。
局限性
- 临床实施前需生成稳健证据,当前证据尚不足以支持常规临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No specific statements regarding the use of 2-[18F]fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography ([18F]FDG PET) in the context of immunotherapy are made in current international oncological guidelines for the management of the two cancer types for which the largest body of evidence has been generated, such as melanoma and non-small cell lung cancer (NSCLC). However, practice guidelines released jointly by leading nuclear medicine societies recommended the use of [18F]FDG PET alongside computed tomography (CT) before immunotherapy initiation, for early response assessment, and in patients considered for therapy discontinuation. In the present paper we critically reviewed the available literature on the comparison between [18F]FDG PET and CT for response assessment in patients undergoing immunotherapy, with the aim to identify where metabolic imaging holds the most significant promise. In early response assessment, where an accurate discrimination between pseudoprogression and true tumor progression is necessary, [18F]FDG PET is of limited value. In contrast, there are at least two clinical scenarios in which [18F]FDG PET could outperform CT because of its high negative predictive value, that are the evaluation of response to neoadjuvant immunotherapy or before therapy discontinuation. We emphasized that the generation of robust evidence is necessary before clinical implementation, as it ensures the optimal allocation of resources and better patient care.
引用
- Santo G, Pozzessere C, Michielin O, et al. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice. Eur J Nucl Med Mol Imaging. 2026. PMID: 42463966. doi:10.1007/s00259-026-08080-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。